BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, João I, Pereira H. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014;7:891. [PMID: 25491419 DOI: 10.1186/1756-0500-7-891] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Zawawi NA, Abdul Halim Zaki I, Ming LC, Goh HP, Zulkifly HH. Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation. Front Cardiovasc Med 2021;8:736143. [PMID: 34869639 DOI: 10.3389/fcvm.2021.736143] [Reference Citation Analysis]
2 Wen X, Wang S, Taveira TH, Akhlaghi F. Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). PLoS One 2021;16:e0251665. [PMID: 34525124 DOI: 10.1371/journal.pone.0251665] [Reference Citation Analysis]
3 Caldeira D, Cruz I, Morgado G, Stuart B, Gomes AC, Martins C, João I, Pereira H. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method? Blood Coagul Fibrinolysis 2015;26:972-6. [PMID: 26083988 DOI: 10.1097/MBC.0000000000000312] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Liyew Z, Tadesse A, Bekele N, Tsegaye T. Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia. Adv Hematol 2021;2021:7530997. [PMID: 34970315 DOI: 10.1155/2021/7530997] [Reference Citation Analysis]
5 Albabtain MA, Alharthi MM, Dagriri K, Arafat AA, Ayrout E, Alhebaishi Y, AlFagih A. Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J 2020;41:1245-51. [PMID: 33130846 DOI: 10.15537/smj.2020.11.25456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Marcatto LR, Sacilotto L, Bueno CT, Facin M, Strunz CM, Darrieux FC, Scanavacca MI, Krieger JE, Pereira AC, Santos PC. Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. BMC Cardiovasc Disord 2016;16:224. [PMID: 27855643 DOI: 10.1186/s12872-016-0405-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Barón-esquivias G, Fernández-avilés F, Atienza F, Pastor Pueyo P, Toro R, Sanmartín Fernández M. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 2015;13:341-53. [DOI: 10.1586/14779072.2015.1026259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
8 Kim Y, Park ES, Kang DW, Kim TJ, Lee SH. Maintenance dose of warfarin beyond time in therapeutic range for preventing vascular events. J Neurol Sci 2019;398:69-74. [PMID: 30684767 DOI: 10.1016/j.jns.2019.01.031] [Reference Citation Analysis]
9 Chaudhary R, Sharma T, Garg J, Sukhi A, Bliden K, Tantry U, Turagam M, Lakkireddy D, Gurbel P. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis 2020;49:271-86. [PMID: 31512202 DOI: 10.1007/s11239-019-01954-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 11.5] [Reference Citation Analysis]
10 Marcatto LR, Sacilotto L, Darrieux FC, Hachul DT, Scanavacca MI, Krieger JE, Pereira AC, Santos PC. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. Oncotarget 2016;7:54194-9. [PMID: 27486984 DOI: 10.18632/oncotarget.10944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Caldeira D, Rodrigues R, Abreu D, Anes AM, Rosa MM, Ferreira JJ. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. Expert Opinion on Drug Safety 2018;17:339-45. [DOI: 10.1080/14740338.2018.1439474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
12 Lee SY, Cherian R, Ly I, Horton C, Salley AL, Sarkar U. Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting. Jt Comm J Qual Patient Saf 2017;43:353-60. [PMID: 28648221 DOI: 10.1016/j.jcjq.2017.03.006] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Masresha N, Muche EA, Atnafu A, Abdela O. Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia. J Blood Med 2021;12:189-95. [PMID: 33790682 DOI: 10.2147/JBM.S282948] [Reference Citation Analysis]
14 Guedes M, Rego C. Estudo HIPOGAIA: monitorização da hipocoagulação oral com dicumarínicos no concelho de Gaia. Revista Portuguesa de Cardiologia 2016;35:459-65. [DOI: 10.1016/j.repc.2016.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Lip GYH. The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. Int J Clin Pract 2019;73:e13285. [DOI: 10.1111/ijcp.13285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Goldstein LN, Wu MT. A one year audit of patients with venous thromboembolism presenting to a tertiary hospital in Johannesburg, South Africa. Afr J Emerg Med 2018;8:12-5. [PMID: 30456139 DOI: 10.1016/j.afjem.2017.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Katerenchuk V, Duarte GS, Martins E Pereira G, Fernandes RM, Ferreira JJ, Pinto FJ, Costa J, Caldeira D. Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis. Thromb Haemost 2021;121:366-82. [PMID: 33160289 DOI: 10.1055/s-0040-1716752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Caldeira D, Ferreira JJ, Pinto FJ. The era of the novel oral anticoagulants in Portugal. Rev Port Cardiol 2017;36:577-8. [PMID: 28687366 DOI: 10.1016/j.repc.2016.12.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
19 Caldeira D, Nunes-Ferreira A, Rodrigues R, Vicente E, Pinto FJ, Ferreira JJ. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr 2019;81:209-14. [PMID: 30612074 DOI: 10.1016/j.archger.2018.12.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
20 Al Ammari M, AlThiab K, AlJohani M, Sultana K, Maklhafi N, AlOnazi H, Maringa A. Tele-pharmacy Anticoagulation Clinic During COVID-19 Pandemic: Patient Outcomes. Front Pharmacol 2021;12:652482. [PMID: 34566632 DOI: 10.3389/fphar.2021.652482] [Reference Citation Analysis]
21 Liu S, Li X, Shi Q, Hamilton M, Friend K, Zhao Y, Horblyuk R, Hede S, Shi L. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. Current Medical Research and Opinion 2018;34:415-21. [DOI: 10.1080/03007995.2017.1384370] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
22 Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia. Clin Appl Thromb Hemost 2021;27:10760296211049786. [PMID: 34724849 DOI: 10.1177/10760296211049786] [Reference Citation Analysis]
23 Mohammed S, Aljundi AH, Kasem M, Alhashemi M, El-Menyar A. Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. J Adv Pharm Technol Res 2017;8:14-8. [PMID: 28217549 DOI: 10.4103/2231-4040.197370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98:393-397. [PMID: 28009449 DOI: 10.1111/ejh.12844] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 15.2] [Reference Citation Analysis]
25 Tan CSY, Fong AYY, Jong YH, Ong TK. INR Control of Patients with Mechanical Heart Valve on Long-Term Warfarin Therapy. Glob Heart 2018;13:241-4. [PMID: 30213574 DOI: 10.1016/j.gheart.2018.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]